# Enzymaster (Ningbo) Bio-Engineering Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enzymaster-ningbo-bio-engineering-co

- Industry: Biotechnology
- Headquarters: Ningbo, China
- Website: www.enzymaster.com
- Total disclosed funding: $24M
- Latest round: Series C (Jan 24, 2022)
- Investors on record: 8

## About

Established in 2013 and based in Ningbo, China, Enzymaster (Ningbo) Bio-Engineering Co., Ltd. is a bio-catalysis solution provider that focuses on the development and commercialization of enzymatic and microbial catalysis technology. Enzymaster (Ningbo) Bio-Engineering Co., Ltd. has completed a round B financing of RMB 100 million. The company has completed 7 rounds of funding as of 2022. The chairman Dr. Yongkai Huang has a PhD in medicinal chemistry from the National University of Singapore and more than 10 years of R&D experience in the bio-intelligence industry. He worked for Codexis.

The company provides biocatalysts solution and  enzyme catalytic technology. The company has built up a stockpile of many enzymes. At present, there are 15 pharmaceutical intermediates and food additives that have been commercialized. In addition, the company has involved in the fields of pesticides, veterinary drugs, flavors and fragrances, materials and RNA synthesis. The company's main business is R&D, design, manufacturing and sales of various catalytic enzymes.

## Funding rounds

- Series C, Jan 24, 2022, $24M — YuanBio Venture, Puhua Capital, Xiamen C&D Emerging Industry Equity Investment, Probe New Medical Fund
- Series C, Nov 26, 2021 — Kangjun Capital
- Series A, Mar 24, 2018 — Fortune Capital, Ningbo intellectual property fund, Saisheng investment

## Investors

- Fortune Capital — Series A
- Ningbo intellectual property fund — Series A
- Saisheng investment — Series A
- Kangjun Capital (https://capitalatlas.ai/funds/kangjun-capital) — Series C
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series C
- Puhua Capital (https://capitalatlas.ai/funds/puhua-capital) — Series C
- Xiamen C&D Emerging Industry Equity Investment (https://capitalatlas.ai/funds/xiamen-c-d-emerging-industry-equity-investment) — Series C
- Probe New Medical Fund — Series C